GU Cancers 2019 | SPIRE trial: overcoming cisplatin resistance in bladder cancer with transcriptome changes

Simon Crabb

Although cisplatin-based combination chemotherapy has proved to be an effective standard of care therapy for urothelial bladder cancer, tumor resistance to cisplatin remains a major challenge. Simon Crabb, MBBS, MRCP, PhD, of the University of Southampton, Southampton, UK, talks about his investigation on evaluating the efficacy of guadecitabine, a DNA hypomethylating agent, in preventing cisplatin resistance in bladder cancer patients. The performance of guadecitabine was studied in SPIRE, a Phase IB/randomized IIA open-label clinical trial (ISRCTN16332228). This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video